文献速递皮肤肿瘤银屑病与炎症性皮肤病

晚期蕈样肉芽肿与Sézary综合征的CLIPI预后指数与风险分层

Cutaneous Lymphoma International Prognostic Index and Risk Stratification in Advanced Mycosis Fungoides and Sézary Syndrome.
PubMed 文献 · JAMA Dermatol · 2026-10-07

这项国际前瞻性队列研究纳入277例IIB-IVB期蕈样肉芽肿与Sézary综合征患者,评估CLIPI预后指数对无进展生存期和最佳客观缓解的预测价值。结果显示低、中、高危组中位PFS分别为4.64、2.72和0.89年,CLIPI每增加1分与观察到更好缓解的几率降低约38%相关,提示CLIPI可超越临床分期改善风险分层。

要点

  • CLIPI低、中、高危组中位PFS分别为4.64、2.72和0.89年,组间差异显著。
  • 中危和高危组进展或死亡风险分别为低危组的1.45倍和3.84倍。
  • CLIPI每增加1分,随访期间观察到更好缓解的几率降低约38%。

核心结论

  • 在晚期MF/SS国际前瞻性队列中,CLIPI评分与疾病进展风险和缓解可能性相关,且超越临床分期。
  • CLIPI可能有助于细化风险分层,支持其整合进临床决策和未来试验设计。

研究设计与样本

  • 国际前瞻性队列研究,数据来自PROCLIPI试验,2015年7月1日至2025年5月1日,覆盖46个转诊中心。
  • 纳入277例IIB至IVB期MF/SS患者,中位随访4.75年(95%CI,4.04-5.13)。

主要发现

  • 低危144例(52.0%)、中危93例(33.6%)、高危40例(14.4%),中位PFS分别为4.64年(95%CI,3.50-5.76)、2.72年(95%CI,1.81-4.56)、0.89年(95%CI,0.65-1.14)(log-rank P < .001)。
  • 中危组进展或死亡HR为1.45(95%CI,1.01-2.08),高危组HR为3.84(95%CI,2.21-6.66),均以低危组为参照。
  • CLIPI加入后较仅含基线分期的模型改善了PFS区分度。
  • CLIPI每增加1分,随访期间观察到更好缓解的比值比为0.62(95%CI,0.43-0.89)。

关键数值与推荐

  • CLIPI评分基于诊断时年龄>60岁、血清乳酸脱氢酶升高、N3淋巴结状态和皮肤大细胞转化。
  • 低危为0或1个因素,中危为2个因素,高危为3或4个因素。

临床怎么用

  • 可将CLIPI评分用于晚期MF/SS诊断时的风险分层,辅助识别进展风险较高或缓解可能性较低的患者。
  • CLIPI可补充临床分期信息,支持将其纳入临床决策和未来试验设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Risk stratification in advanced mycosis fungoides and Sézary syndrome (MF/SS) remains suboptimal given that current TNMB (tumor, node, metastasis, blood) staging has limited prognostic value for clinically relevant outcomes. OBJECTIVE: To determine whether the Cutaneous Lymphoma International Prognostic Index (CLIPI) may be used to predict progression-free survival (PFS) and best objective response (BOR) in patients with advanced MF/SS. DESIGN, SETTING, AND PARTICIPANTS: This international prospective cohort study included patients with stage IIB to IVB MF/SS from the PROCLIPI trial which ran from July 1, 2015, to May 1, 2025, across 46 referral centers. Median follow-up was 4.75 (95% CI, 4.04-5.13) years; eligible participants had complete data on CLIPI, PFS, and BOR. Data were analyzed from September 1 to December 1, 2025. EXPOSURE: CLIPI score at diagnosis, based on age (>60 years), elevated serum lactate dehydrogenase, N3 nodal status, and large-cell transformation in the skin. Patients were classified as having low (0 or 1 factor), intermediate (2 factors), or high risk (3 or 4 factors). MAIN OUTCOMES AND MEASURES: PFS (defined as diagnosis to disease progression or death) and BOR (complete response, partial response, stable disease, or progressive disease) during follow-up. Exploratory analyses evaluated treatment effects before progression using inverse probability weighting. RESULTS: Among 277 patients (median [IQR] age at diagnosis, 66 [23-89] years; 183 male individuals [65.7%]), 144 (52.0%) were classified as having low risk, 93 (33.6%) intermediate risk, and 40 (14.4%) high risk. They had a median PFS of 4.64 years (95% CI, 3.50-5.76), 2.72 years (95% CI, 1.81-4.56), and 0.89 years (95% CI, 0.65-1.14), respectively (log-rank P < .001). Patients in the intermediate-risk (hazard ratio [HR], 1.45; 95% CI, 1.01-2.08) and high-risk (HR, 3.84; 95% CI, 2.21-6.66) CLIPI groups displayed higher hazards of progression or death than those at low risk. Inclusion of CLIPI improved PFS discrimination over a model with baseline stage alone. Each 1-point increase in CLIPI was associated with approximately 38% lower odds of observing a better response during follow-up (odds ratio, 0.62; 95% CI, 0.43-0.89). CONCLUSIONS AND RELEVANCE: In this international prospective cohort of patients with advanced MF/SS, CLIPI scores were associated with risk of disease progression and likelihood of response beyond clinical stage. These findings indicate that CLIPI may help to refine risk stratification and support its integration into clinical decision-making and future trial design.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Roccuzzo G, Bashir A, Evison F, et al. Cutaneous Lymphoma International Prognostic Index and Risk Stratification in Advanced Mycosis Fungoides and Sézary Syndrome. JAMA Dermatol. 2026. PMID: 42842270. doi:10.1001/jamadermatol.2026.3856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。